Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors

NCT03096340 is registered in ClinicalTrials.gov with Intezyne Technologies, Inc. as lead sponsor.

NCT NCT03096340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03096340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors
Lead sponsor
Intezyne Technologies, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 23, 2017
Completion date
November 26, 2019
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasms, recurrent solid tumors, refractory solid tumors, tumors